Rezolute (RZLT) Operating Expenses (2010 - 2026)
Rezolute recorded quarterly Operating Expenses of $17.4 million in Q1 2026, down 28.3% quarter-over-quarter from $24.2 million in Q4 2025, and down 13.27% year-over-year from $20.0 million in Q1 2025.
Rezolute's Operating Expenses history runs 17 years deep, the most recent figure standing at $17.4 million for Q1 2026.
- In Q1 2026, Operating Expenses fell 13.27% year-over-year to $17.4 million; the TTM figure through Mar 2026 stood at $87.3 million (up 13.1% YoY), while the FY2025 annual figure was $79.9 million, up 13.45% from the prior year.
- Operating Expenses came in at $17.4 million for Q1 2026 at Rezolute, down from $24.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $25.8 million in Q2 2025 to a low of $10.2 million in Q3 2022.
- A 5-year average of $17.0 million and a median of $16.9 million in 2024 frame the typical range for Operating Expenses.
- Across the five-year window, Operating Expenses soared 96.13% in 2022 and slipped 13.27% in 2026, its largest moves.
- Rezolute's Operating Expenses stood at $14.4 million in 2022, then increased by 5.57% to $15.2 million in 2023, then gained by 12.41% to $17.1 million in 2024, then soared by 41.81% to $24.2 million in 2025, then retreated by 28.3% to $17.4 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $17.4 million, $24.2 million, and $19.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | 17.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.37 Mn |
| Dec 31, 2025 | 24.22 Mn |
| Sep 30, 2025 | 19.82 Mn |
| Jun 30, 2025 | 25.85 Mn |
| Mar 31, 2025 | 20.02 Mn |
| Dec 31, 2024 | 17.08 Mn |
| Sep 30, 2024 | 16.94 Mn |
| Jun 30, 2024 | 23.10 Mn |
| Mar 31, 2024 | 16.21 Mn |
| Dec 31, 2023 | 15.19 Mn |
| Sep 30, 2023 | 15.91 Mn |
| Jun 30, 2023 | 14.24 Mn |
| Mar 31, 2023 | 17.14 Mn |
| Dec 31, 2022 | 14.39 Mn |
| Sep 30, 2022 | 10.22 Mn |
| Jun 30, 2022 | 11.30 Mn |
| Mar 31, 2022 | 10.75 Mn |
| Dec 31, 2021 | 12.15 Mn |
| Sep 30, 2021 | 7.64 Mn |
| Jun 30, 2021 | 6.64 Mn |
| Mar 31, 2021 | 5.48 Mn |
| Dec 31, 2020 | 7.15 Mn |
| Sep 30, 2020 | 3.62 Mn |
| Jun 30, 2020 | 3.55 Mn |
| Mar 31, 2020 | 5.07 Mn |
| Dec 31, 2019 | 6.72 Mn |
| Sep 30, 2019 | 5.18 Mn |
| Jun 30, 2019 | 3.18 Mn |
| Mar 31, 2019 | 17.04 Mn |
| Dec 31, 2018 | 3.16 Mn |
| Sep 30, 2018 | 2.56 Mn |
| Jun 30, 2018 | 11.31 Mn |
| Mar 31, 2018 | 4.95 Mn |
| Dec 31, 2017 | 5.75 Mn |
| Sep 30, 2017 | 6.72 Mn |
| Jun 30, 2017 | 6.22 Mn |
| Mar 31, 2017 | 5.39 Mn |
| Dec 31, 2016 | 4.89 Mn |
| Sep 30, 2016 | 3.82 Mn |
| Jun 30, 2016 | 3.87 Mn |
| Mar 31, 2016 | 3.72 Mn |
| Dec 31, 2015 | 4.07 Mn |
| Sep 30, 2015 | 3.30 Mn |
| Jun 30, 2015 | 3.09 Mn |
| Mar 31, 2015 | 2.30 Mn |
| Dec 31, 2014 | 3.07 Mn |
| Sep 30, 2014 | 2.24 Mn |
| Jun 30, 2014 | 2.23 Mn |
| Mar 31, 2014 | 1.60 Mn |
| Dec 31, 2013 | 650,118.00 |
| Sep 30, 2013 | 700,903.00 |
| Jun 30, 2013 | 1.01 Mn |
| Mar 31, 2013 | 4.05 Mn |
| Dec 31, 2012 | 500,065.00 |
| Sep 30, 2012 | 542,882.00 |
| Jun 30, 2012 | 227,901.00 |
| Mar 31, 2012 | 94,596.00 |
| Dec 31, 2011 | 7,998.00 |
| Sep 30, 2011 | 7,394.00 |
| Mar 31, 2011 | 24,407.00 |
| Dec 31, 2010 | 1,751.00 |
| Sep 30, 2010 | 25,000.00 |